Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.

Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).

Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.